## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.8% below STRENGTH zone (3.0-6.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Medtronic (MDT) Stock: Dividend Timing, MiniMed IPO Watch, and What to Know Before the Next NYSE Session**
- Source: ts2.tech | 20251227T213541 | Somewhat-Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) is heading into the weekend with investors considering its recently passed dividend record date, the planned MiniMed IPO to separate its diabetes business, and strong cardiovascular momentum. The stock closed Friday at $96.52, with thin trading volumes typical for the year-end "Santa rally" period. Over the weekend and leading into next week's trading, investors will be focused on MiniMed IPO developments, upcoming macro catalysts like Federal Reserve minutes, and Medtronic's Q3 FY26 earnings report expected around February 17, 2026.

**2. Medtronic PLC $MDT Shares Purchased by SS&H Financial Advisors Inc.**
- Source: MarketBeat | 20251229T123021 | Bullish | Relevance: 100%
- SS&H Financial Advisors Inc. significantly increased its stake in Medtronic PLC, purchasing an additional 10,915 shares that boosted their holdings to 16,371 shares valued at $1.559 million. This occurred as Medtronic announced strong Q3 earnings, beating consensus estimates, and declared a quarterly dividend of $0.71 per share. Analysts generally maintain a "Moderate Buy" rating for Medtronic, with a consensus price target of $109.94.

**3. Ethic Inc. Lowers Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251229T095232 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. has reduced its stake in Medtronic PLC (NYSE:MDT) by 7.5% in the third quarter, selling 11,006 shares and retaining 135,412 shares valued at approximately $12.9 million. This adjustment comes as Medtronic exceeded Q3 earnings expectations, reporting an EPS of $1.36 against a $1.31 consensus, and set its FY2026 EPS guidance between $5.620 and $5.660. The company also announced a quarterly dividend of $0.71 per share with a 2.9% yield.

**4. Medtronic (MDT) Stock Update: Dividend Timing, MiniMed IPO Catalyst, and What Investors Should Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T213828 | Somewhat-Bullish | Relevance: 100%
- This article provides investors with key updates on Medtronic (MDT) ahead of Monday's market open, focusing on its recent stock performance, upcoming dividend schedule, and significant catalysts like the MiniMed IPO and Hugo robotic surgery FDA clearance. It also touches on analyst forecasts and regulatory news impacting the medical technology giant. The overall sentiment suggests a constructive market backdrop for Medtronic, driven by strategic portfolio moves and growth drivers in cardiovascular and robotics.

**5. Medtronic PLC $MDT Shares Purchased by Columbus Macro LLC**
- Source: MarketBeat | 20251228T093634 | Bullish | Relevance: 100%
- Columbus Macro LLC increased its stake in Medtronic PLC (NYSE:MDT) by 19.2% in the third quarter, bringing their total holdings to 85,748 shares valued at $8.17 million. Medtronic recently surpassed earnings expectations with $1.36 EPS and $8.96B revenue, announced a quarterly dividend of $0.71, and boasts a consensus "Moderate Buy" rating from analysts. The medical technology company's stock currently trades at $96.52 with a market capitalization of $123.7 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $123.3B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 15.7 |
| Current P/E | 17.0 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.8% (minimal 5-day change). Below STRENGTH zone by 4.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-0.59), momentum weakening. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.84% (CS: 18) | Neutral |
| RSI_14 | 37.1 | Neutral |
| MACD Histogram | -0.59 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.12
- **Stop Loss:** $93.22 (3.0% risk)
- **Target:** $99.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 475
- **Position Value:** $45,657.00
- **Portfolio %:** 45.66%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*